Atlas Trials

A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)

Clinical trial NCT04502446 · TERMINATED

Trial details

NCT number
NCT04502446
Sponsor
CRISPR Therapeutics AG
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
T Cell Lymphoma
Start date
2020-07-31
Primary completion
2024-08-30
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.